Literature DB >> 11024117

Impaired gamma interferon responses against parvovirus B19 by recently infected children.

A Corcoran1, S Doyle, D Waldron, A Nicholson, B P Mahon.   

Abstract

Parvovirus B19 is the causative agent of "fifth disease" of childhood. It has been implicated in a variety of conditions, including unsuccessful pregnancy and rheumatoid arthritis, and is a potential contaminant of blood products. There has been little study of immunity to parvovirus B19, and the exact nature of the protective humoral and cell-mediated immune response is unclear. Immune responses to purified virus capsid proteins, VP1 and VP2, were examined from a cohort of recently infected children and compared with responses from long-term convalescent volunteers. The results demonstrate that antibody reactivity is primarily maintained against conformational epitopes in VP1 and VP2. The unique region of VP1 appears to be a major target for cell-mediated immune responses, particularly in recently infected individuals. We confirm that antibody reactivity against linear epitopes of VP2 is lost shortly after infection but find no evidence of the proposed phenotypic switch in either the subclass of parvovirus B19-specific antibody or the pattern of cytokine production by antigen-specific T cells. The dominant subclass of specific antibody detected from both children and adults was immunoglobulin G1. No evidence was found for interleukin 4 (IL-4) or IL-5 production by isolated lymphocytes from children or adults. In contrast, lymphocytes from convalescent adults produced a typical type 1 response associated with high levels of IL-2 and gamma interferon (IFN-gamma). However, we observed a significant (P<0.001) deficit in the production of IFN-gamma in response to VP1 or VP2 from lymphocytes isolated from children. Taken together, these results imply that future parvovirus B19 vaccines designed for children will require the use of conformationally preserved capsid proteins incorporating Th1 driving adjuvants. Furthermore, these data suggest novel mechanisms whereby parvovirus B19 infection may contribute to rheumatoid arthritis and unsuccessful pregnancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024117      PMCID: PMC102027          DOI: 10.1128/jvi.74.21.9903-9910.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

Review 1.  Approaches to new vaccines.

Authors:  B P Mahon; A Moore; P A Johnson; K H Mills
Journal:  Crit Rev Biotechnol       Date:  1998       Impact factor: 8.429

2.  Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Authors:  M Ryan; G Murphy; E Ryan; L Nilsson; F Shackley; L Gothefors; K Oymar; E Miller; J Storsaeter; K H Mills
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

Review 3.  Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells.

Authors:  J G Tew; J Wu; D Qin; S Helm; G F Burton; A K Szakal
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

4.  Intrauterine parvovirus infection associated with hydrops fetalis.

Authors:  T Brown; A Anand; L D Ritchie; J P Clewley; T M Reid
Journal:  Lancet       Date:  1984-11-03       Impact factor: 79.321

Review 5.  Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?

Authors:  T G Wegmann; H Lin; L Guilbert; T R Mosmann
Journal:  Immunol Today       Date:  1993-07

6.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.

Authors:  M Söderlund; C S Brown; W J Spaan; L Hedman; K Hedman
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

7.  Recurrent lymphocytic meningitis associated with hereditary isolated IgG subclass 3 deficiency.

Authors:  J A Snowden; A Milford-Ward; L J Cookson; M W McKendrick
Journal:  J Infect       Date:  1993-11       Impact factor: 6.072

8.  Specificity of predominant IgG4 antibodies to adult and microfilarial stages of Brugia malayi.

Authors:  A Kurniawan-Atmadja; E Sartono; F Partono; M Yazdanbakhsh; R Maizels
Journal:  Parasite Immunol       Date:  1998-04       Impact factor: 2.280

9.  Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro.

Authors:  N Young; M Harrison; J Moore; P Mortimer; R K Humphries
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

10.  Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection.

Authors:  A D Wagner; J J Goronzy; E L Matteson; C M Weyand
Journal:  Mayo Clin Proc       Date:  1995-03       Impact factor: 7.616

View more
  10 in total

1.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

2.  Long term follow up of serostatus after maternofetal parvovirus B19 infection.

Authors:  J Dembinski; A M Eis-Hübinger; J Maar; R Schild; P Bartmann
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

3.  Immune responses to the major capsid protein during parvovirus infection of rats.

Authors:  Lisa J Ball-Goodrich; Frank X Paturzo; Elizabeth A Johnson; Krista Steger; Robert O Jacoby
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 4.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

5.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

6.  Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19.

Authors:  Victoria Kasprowicz; Adiba Isa; Thomas Tolfvenstam; Katie Jeffery; Paul Bowness; Paul Klenerman
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

7.  Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation.

Authors:  Whitney Besse; Sherry Mansour; Karan Jatwani; Cynthia C Nast; Ursula C Brewster
Journal:  BMC Nephrol       Date:  2016-09-06       Impact factor: 2.388

8.  Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis.

Authors:  Milda Naciute; Diana Mieliauskaite; Rita Rugiene; Rita Nikitenkiene; Ligita Jancoriene; Mykolas Mauricas; Zaiga Nora-Krukle; Modra Murovska; Irute Girkontaite
Journal:  J Gen Virol       Date:  2016-10-07       Impact factor: 3.891

9.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891

Review 10.  Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome.

Authors:  Jonathan R Kerr; David A J Tyrrell
Journal:  Curr Pain Headache Rep       Date:  2003-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.